Comparison of efficacy and safety of escitalopram and vilazodone in major depressive disorder
Journal Title: National Journal of Physiology, Pharmacy and Pharmacology - Year 2018, Vol 8, Issue 8
Abstract
Background: Major depressive disorder (MDD) is a worldwide prevalent psychiatric ailment associated with significant morbidity and mortality. Escitalopram is an effective selective serotonin reuptake inhibitor (SSRI), and vilazodone is a newer SSRI and partial serotonin receptor agonist approved for MDD. Aims and Objectives: The aim was to evaluate and compare the efficacy and safety of escitalopram and vilazodone in patients of MDD. Materials and Methods: The present, randomized study was conducted in a tertiary care teaching institute, and 50 patients between 18 and 55 years of either sex diagnosed with MDD based on Diagnostic and Statistical Manual of Mental Disorders Fifth Edition criteria were included in the study. Patients were assigned randomly into two groups to receive orally either escitalopram (10 mg) or vilazodone (20 mg) and baseline scores of Hamilton Anxiety Scale (HAM–A) and Hamilton Depression Rating Scale (HAM-D) were recorded. These were then assessed at 6 weeks for post-drug scores and compared with baseline using Mann–Whitney and Wilcoxon signed-rank test statistical analytic method. Intergroup comparison was also done. Results: Average age of the patients taken was 39.74 ± 8.6 years with a male:female ratio of 19:31. The HAM-D score was significantly lowered by both escitalopram and vilazodone (P < 0.0001). HAM-A score was also similarly lowered by escitalopram (P < 0.0001) and vilazodone (P < 0.0001). On intergroup comparison, escitalopram was found to cause more lowering of HAM-D score and HAM-A score than vilazodone (P < 0.0001). Biochemical profile (blood sugar, serum urea, creatinine, hemoglobin, and total leukocyte counts) was not altered with either of the drugs over 6 weeks. No significant adverse drug reactions were noted with the drugs. Conclusion: Both drugs are effective in decreasing depression and anxiety scores in patients of MDD. On comparison, escitalopram was found better than vilazodone.
Authors and Affiliations
Palvi Kudyar, Brij Mohan Gupta, Vijay Khajuria, Rakesh Banal
Keywords
Related Articles
- EP ID EP491235
- DOI 10.5455/njppp.2018.8.0412120042018
- Views 86
- Downloads 0
Does smoking affect intraocular pressure? A cross-sectional study
Background: Tobacco smoking is linked to ocular conditions such as cataract, age-related macular degeneration, and glaucoma. Glaucoma is the most common cause of irreversible blindness and the second most common cause of...
Galvanic skin resistance in different phases of menstrual cycle in acne vulgaris
Background: Galvanic skin response (GSR) is altered by sympathetic dominance and increased sympathetic activity will cause decrease in GSR. Skin conductance varies with different phases of menstrual cycle. Measuring skin...
Comparative study of simple auditory reaction time in blind and blindfolded sighted individuals
Background: The ability of blinds to adapt themselves to cope with environmental stimuli depends on the quickness of response which in turn depends on sensory perception and central processing. Aims and Objectives: In th...
Study of visual evoked potentials in patients with type 2 diabetes mellitus and diabetic retinopathy
Background: Type 2 diabetes mellitus (T2DM) is a metabolic disorder showing an increasing trend with an increase in complications such as diabetic retinopathy (DR), which can cause blindness. Most patients do not notice...
Formulation of tomato extracts (Solanum lycopersicum L.) as a sunscreen lotion
Background: Tomato (Solanum lycopersicum L) has sunscreen efficacy consisting of lycopene which can provide ultraviolet (UV) irradiation in sunlight and protect skin from UV B induces photodamage. Objective: This work ai...